-DOCSTART- -X- O
Immune‐mediated -X- _ B-Intervention
hemolytic -X- _ I-Intervention
anemia -X- _ I-Intervention
( -X- _ I-Intervention
IMHA -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
an -X- _ O
important -X- _ O
cause -X- _ O
of -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
in -X- _ O
dogs. -X- _ B-Patient
IMHA -X- _ O
also -X- _ O
occurs -X- _ O
in -X- _ O
cats -X- _ B-Patient
, -X- _ O
although -X- _ O
less -X- _ O
commonly. -X- _ O
IMHA -X- _ O
is -X- _ O
considered -X- _ O
secondary -X- _ O
when -X- _ O
it -X- _ O
can -X- _ O
be -X- _ O
attributed -X- _ O
to -X- _ O
an -X- _ O
underlying -X- _ O
disease -X- _ O
, -X- _ O
and -X- _ O
as -X- _ O
primary -X- _ O
( -X- _ O
idiopathic -X- _ O
) -X- _ O
if -X- _ O
no -X- _ O
cause -X- _ O
is -X- _ O
found. -X- _ O
Eliminating -X- _ O
diseases -X- _ O
that -X- _ O
cause -X- _ O
IMHA -X- _ O
may -X- _ O
attenuate -X- _ O
or -X- _ O
stop -X- _ O
immune‐mediated -X- _ O
erythrocyte -X- _ O
destruction -X- _ O
, -X- _ O
and -X- _ O
adverse -X- _ O
consequences -X- _ O
of -X- _ O
long‐term -X- _ O
immunosuppressive -X- _ O
treatment -X- _ O
can -X- _ O
be -X- _ O
avoided. -X- _ O
Infections -X- _ O
, -X- _ O
cancer -X- _ O
, -X- _ O
drugs -X- _ O
, -X- _ O
vaccines -X- _ O
, -X- _ O
and -X- _ O
inflammatory -X- _ O
processes -X- _ O
may -X- _ O
be -X- _ O
underlying -X- _ O
causes -X- _ O
of -X- _ O
IMHA. -X- _ O
Evidence -X- _ O
for -X- _ O
these -X- _ O
comorbidities -X- _ O
has -X- _ O
not -X- _ O
been -X- _ O
systematically -X- _ O
evaluated -X- _ O
, -X- _ O
rendering -X- _ O
evidence‐based -X- _ O
decisions -X- _ O
difficult. -X- _ O
We -X- _ O
identified -X- _ O
and -X- _ O
extracted -X- _ O
data -X- _ O
from -X- _ O
studies -X- _ O
published -X- _ O
in -X- _ O
the -X- _ O
veterinary -X- _ O
literature -X- _ O
and -X- _ O
developed -X- _ O
a -X- _ O
novel -X- _ O
tool -X- _ O
for -X- _ O
evaluation -X- _ O
of -X- _ O
evidence -X- _ O
quality -X- _ O
, -X- _ O
using -X- _ O
it -X- _ O
to -X- _ O
assess -X- _ O
study -X- _ O
design -X- _ O
, -X- _ O
diagnostic -X- _ O
criteria -X- _ O
for -X- _ O
IMHA -X- _ O
, -X- _ O
comorbidities -X- _ O
, -X- _ O
and -X- _ O
causality. -X- _ O
Succinct -X- _ O
evidence -X- _ O
summary -X- _ O
statements -X- _ O
were -X- _ O
written -X- _ O
, -X- _ O
along -X- _ O
with -X- _ O
screening -X- _ O
recommendations. -X- _ O
Statements -X- _ O
were -X- _ O
refined -X- _ O
by -X- _ O
conducting -X- _ O
3 -X- _ O
iterations -X- _ O
of -X- _ O
Delphi -X- _ O
review -X- _ O
with -X- _ O
panel -X- _ O
and -X- _ O
task -X- _ O
force -X- _ O
members. -X- _ O
Commentary -X- _ O
was -X- _ O
solicited -X- _ O
from -X- _ O
several -X- _ O
professional -X- _ O
bodies -X- _ O
to -X- _ O
maximize -X- _ O
clinical -X- _ O
applicability -X- _ O
before -X- _ O
the -X- _ O
recommendations -X- _ O
were -X- _ O
submitted. -X- _ O
The -X- _ O
resulting -X- _ O
document -X- _ O
is -X- _ O
intended -X- _ O
to -X- _ O
provide -X- _ B-Outcome
clinical -X- _ I-Outcome
guidelines -X- _ I-Outcome
for -X- _ I-Outcome
diagnosis -X- _ I-Outcome
of -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
underlying -X- _ I-Outcome
disease -X- _ I-Outcome
screening -X- _ I-Outcome
for -X- _ I-Outcome
, -X- _ I-Outcome
IMHA -X- _ I-Outcome
in -X- _ I-Outcome
dogs -X- _ I-Outcome
and -X- _ I-Outcome
cats. -X- _ I-Outcome
These -X- _ I-Outcome
should -X- _ I-Outcome
be -X- _ I-Outcome
implemented -X- _ I-Outcome
with -X- _ I-Outcome
consideration -X- _ I-Outcome
of -X- _ I-Outcome
animal -X- _ I-Outcome
, -X- _ I-Outcome
owner -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
geographical -X- _ I-Outcome
factors -X- _ I-Outcome
. -X- _ O

